About
Avalyn Pharma Inc.
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs.
Its current pipeline is focused on treating pulmonary fibrosis.
Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms.
Avalyn Pharma Inc. Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Change from offer price to today
Live Market Snapshot
Real-time price; headline % change is vs first trade (listing price)
USD · NASDAQ:NASDAQ:AVLN
Valuation & Multiples
Key valuation ratios and metrics
Financial Health
Balance sheet strength and liquidity
Profitability & Returns
Margins and return on capital
Financial Highlights
Historical financial performance
Historical Data
Market history and supplemental quote data
| Date | Open | High | Low | Close | Adj. Close | Change | Volume |
|---|---|---|---|---|---|---|---|
| 2026-05-14 | $30.77 | $31.34 | $28.80 | $30.62 | $30.62 | -0.15 | 178,200 |
| 2026-05-13 | $29.92 | $32.23 | $28.36 | $30.83 | $30.83 | +0.91 | 402,300 |
| 2026-05-12 | $29.27 | $31.02 | $29.25 | $29.90 | $29.90 | +0.63 | 308,600 |
| 2026-05-11 | $27.28 | $30.43 | $27.27 | $29.57 | $29.57 | +2.29 | 306,700 |
| 2026-05-08 | $26.66 | $29.00 | $26.64 | $27.33 | $27.33 | +0.67 | 290,400 |
| 2026-05-07 | $27.43 | $27.50 | $25.39 | $26.93 | $26.93 | -0.50 | 664,400 |
| 2026-05-06 | $27.16 | $27.74 | $25.05 | $27.71 | $27.71 | +0.55 | 673,800 |
| 2026-05-05 | $29.32 | $29.64 | $25.44 | $27.43 | $27.43 | -1.89 | 468,000 |
| 2026-05-04 | $30.14 | $30.67 | $28.01 | $29.07 | $29.07 | -1.07 | 357,300 |
| 2026-05-01 | $28.00 | $30.00 | $27.50 | $29.84 | $29.84 | +1.84 | 830,000 |
| 2026-04-30 | $26.00 | $30.20 | $26.00 | $29.49 | $29.49 | +3.49 | 6,512,000 |
SEC Filings
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| SCHEDULE 13D | May 8, 2026 | Filing |
| SCHEDULE 13D | May 8, 2026 | Filing |
| SCHEDULE 13G | May 7, 2026 | Filing |
| SCHEDULE 13G | May 5, 2026 | Filing |
| 8-K | May 1, 2026 | Current Report |
| S-8 | Apr 30, 2026 | Securities to be offered to employees in employee benefit plans |
| 424B4 | Apr 30, 2026 | Prospectus |
| EFFECT | Apr 29, 2026 | Notice of Effectiveness |
| CERT | Apr 29, 2026 | Certification by an exchange approving securities for listing |
| S-1/A | Apr 29, 2026 | [Amend] General form for registration of securities under the Securities Act of 1933 |
Company Info
Contact and headquarters details
Leadership
Key executives and officers
Lyn Baranowski
Chief Executive Officer and Director
Douglas Carlson
Chief Financial Officer and Chief Business Officer
Melissa Rhodes, Ph.D., D.A.B.T
Chief Operating Officer
Howard M. Lazarus, M.D., FCCP
Chief Medical Officer
Heather Turner
Director and Board Chair
Tiba Aynechi, Ph.D.
Director
Jill Carroll
Director
Jon Congleton
Director
David Friedman, M.D.
Director
Kate Haviland
Director
